Key facts
- Gazella Biotech’s last known valuation is $230K (Dec 2024).
- It has raised $60K; the latest was Early Stage VC ($60K) in Dec 2024.
- Notable investors include Banco Santander, Unirisco.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Gazella Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Gazella Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gazella Biotech
Operator of a biotechnology company intended to develop advanced therapies for the treatment of metabolic diseases. The company combats the problem of obesity, regulating the central mechanisms that control metabolism, enabling clients to eliminate unwanted side effects.
- Sector
- Healthcare
- HQ
- Santiago de Compostela, Spain
- Founded
- 2024
- Website
- gazellabiotech.com/
- Ownership
- Privately Held (backing)
Gazella Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gazella Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gazella Biotech in its N-PORT filings yet. We sweep new filings monthly.